BioCardia (BCDA) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioCardia (BCDA) has outperformed TScan Therapeutics (TCRX) over the past year, losing 25.4% versus a loss of 88.5%. Over five years, TCRX leads with a -96.6% price change compared with -97.6% for BCDA. BioCardia is the larger company by market cap ($16.0 million vs $15.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCDA | TCRX |
|---|---|---|
| Share price | $1.06 | $0.2282 |
| Market cap | $16.05M | $15.47M |
| 1-day change | -2.75% | -17.59% |
| YTD return | -15.20% | -77.18% |
| 1-year return | -25.35% | -88.47% |
| 5-year return | -97.59% | -96.62% |
| EPS (TTM) | $-0.64 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.80 | $2.57 |
| 52-week low | $0.75 | $0.224 |
| Distance from 52-week high | -41.11% | -91.12% |
| Analyst consensus | none | hold |
| Avg. price target upside | +1362.26% | +338.21% |
| Average volume | 282.05K | 783.59K |
| Shares outstanding | 15.14M | 63.50M |
| Employees | 17 | 138 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCDA has outperformed TCRX by 63.1 percentage points over the past year.
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Healthcare · Biotechnology · 17 employees
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Healthcare · Biotechnology · 138 employees
BCDA vs TCRX FAQ
Which is bigger, BioCardia or TScan Therapeutics?
BioCardia (BCDA) is larger, with a market capitalization of $16.05M compared with $15.47M for TScan Therapeutics (TCRX).
Which stock has performed better over the past year, BCDA or TCRX?
BCDA returned -25.35% over the past 12 months, compared with -88.47% for TCRX (price return, excluding dividends). Past performance does not predict future results.
Are BioCardia and TScan Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.